Top

Published in:

01-05-2000

CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer

Authors: Christopher W. Ryan, Keith L. Shulman, Jon M. Richards, John W. Kugler, Jeffrey A. Sosman, Rafat H. Ansari, Everett E. Vokes, Nicholas J. Vogelzang

Published in: Investigational New Drugs | Issue 2/2000

Title: CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer
Authors: Christopher W. Ryan
Keith L. Shulman
Jon M. Richards
John W. Kugler
Jeffrey A. Sosman
Rafat H. Ansari
Everett E. Vokes
Nicholas J. Vogelzang
Publication date: 01-05-2000
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006382014403

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2000

A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)

Chemotherapy in Non-Small Cell Lung Cancer

DNA G-Quadruplexes, Telomere-Specific Proteins and Telomere-Associated Enzymes as Potential Targets for New Anticancer Drugs

UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines

A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma

Proteasome Inhibition: a New Strategy in Cancer Treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer